Clinical trial
Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate…
NCT00388063 · Callisto Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00388063 |
|---|---|
| Title | Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma |
| Official title | A Phase II Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma |
| Lead sponsor | Callisto Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroendocrine Carcinoma |
| Intervention type | Drug |
| Interventions | Atiprimod |
| Enrollment | 55 |
| Start date | Oct 1, 2006 |
| Completion | Sep 1, 2007 |
| First posted | Oct 13, 2006 |
| Last update posted | Dec 21, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: